Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 15,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $29.46, for a total transaction of $441,900.00. Following the completion of the sale, the chief marketing officer owned 15,000 shares in the company, valued at $441,900. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Friday, March 20th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $49.10, for a total transaction of $736,500.00.
• On Tuesday, March 10th, Harold Bernstein sold 30,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $50.45, for a total transaction of $1,513,500.00.
• On Monday, February 2nd, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $46.02, for a total transaction of $690,300.00.
• On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.20, for a total transaction of $1,011,271.20.
• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.00, for a total transaction of $16,480.00.
• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.43, for a total transaction of $179,185.76.

Maze Therapeutics Stock Down 1.2%

Shares of MAZE traded down $0.34 during trading hours on Thursday, reaching $28.71. The stock had a trading volume of 780,343 shares, compared to its average volume of 709,583. The company has a market cap of $1.43 billion, a P/E ratio of -8.89 and a beta of 5.14. Maze Therapeutics, Inc. has a 52 week low of $6.71 and a 52 week high of $53.65. The firm has a 50-day moving average of $44.79 and a 200 day moving average of $37.94.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08.

Institutional Trading of Maze Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MAZE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Maze Therapeutics in the first quarter worth $57,000. Goldman Sachs Group Inc. acquired a new position in Maze Therapeutics during the first quarter worth $145,000. Rhumbline Advisers bought a new position in Maze Therapeutics in the first quarter valued at $80,000. Geode Capital Management LLC grew its position in Maze Therapeutics by 8.8% in the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after purchasing an additional 18,773 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after buying an additional 3,371 shares during the last quarter.

Analyst Ratings Changes

MAZE has been the subject of a number of research reports. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Wedbush lifted their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective for the company. Finally, Truist Financial assumed coverage on shares of Maze Therapeutics in a report on Tuesday, March 17th. They set a “buy” rating and a $68.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $66.44.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.